Genotypic and phenotypic predictors of inflammation in patients with chronic kidney disease

Nephrology Dialysis Transplantation

Volumn 31, Issue 12, 2016, Pages 2033-2040

  Luttropp, Karin ^a   Debowska, Malgorzata ^b   Lukaszuk, Tomasz ^c   Bobrowski, Leon ^b,c   Carrero, Juan Jesus ^a   Qureshi, Abdul Rashid ^a   Stenvinkel, Peter ^a   Lindholm, Bengt ^a   Waniewski, Jacek ^b   Nordfors, Louise ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b INSTITUTE OF BIOCYBERNETICS AND BIOMEDICAL ENGINEERING   (Poland)

^c BIALYSTOK UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Biomarkers; Dialysis; End stage renal disease; Gene polymorphism; Inflammation; Relaxed linear separability

Indexed keywords

BIOLOGICAL MARKER; FIBRINOGEN;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; BIOCHEMISTRY; BMP2 GENE; BONE DENSITY; CHRONIC KIDNEY FAILURE; CIITA GENE; CLINICAL FEATURE; CONTROLLED STUDY; DIALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENE; GENOTYPE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NAMPT GENE; PHENOTYPE; PIK3CB GENE; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; COMPLICATION; GENETICS; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADULT; AGED; BIOMARKERS; BONE DENSITY; FEMALE; GENOTYPE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; YOUNG ADULT;

EID: 85020578886     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfw066     Document Type: Article

References (65)

1. Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-2128
2. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305
3. Kooman JP, Kotanko P, Schols AM et al. Chronic kidney disease and premature ageing. Nat Rev Nephrol 2014; 10: 732-742
4. Carrero JJ, Stenvinkel P. Inflammation in end-stage renal disease-what have we learned in 10 years? Semin Dial 2010; 23: 498-509
5. Devuyst O, Knoers NV, Remuzzi G et al. Rare inherited kidney diseases: challenges, opportunities, and perspectives. Lancet 2014; 383: 1844-1859
6. Muntinghe FL, Verduijn M, Zuurman MW et al. CCR5 deletion protects against inflammation-associated mortality in dialysis patients. J Am Soc Nephrol 2009; 20: 1641-1649
7. Bobrowski L, Lukaszuk T, Lindholm B et al. Selection of genetic and phenotypic features associated with inflammatory status of patients on dialysis using relaxed linear separability method. PLoS One 2014; 9: e86630
8. Stenvinkel P, Heimburger O, Paultre F et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899-1911
9. Bobrowski L, Lukaszuk T. Feature selection based on relaxed linear separability. Biocybern Biomed Eng 2009; 29: 43-59
10. Kononenko I. Estimating attributes: analysis and extensions of relief. In: Bergadano F, de Raedt L (eds). Machine Learning: ECML-94. 1 edn. Berlin/Heidelberg: Springer-Verlag, 1994, pp. 171-182
11. Kira K, Rendell LA. A practical approach to feature selection. In: Sleeman D, Edwards P (eds). ML92 Proceedings of the Ninth International Workshop on Machine Learning. San Francisco: Morgan Kaufmann, 1992, pp. 249-256
12. Hall MA. Correlation-based feature selection for discrete and numeric class machine learning. In: Langley P (ed). ICML '00 Proceedings of the Seventeenth International Conference on Machine Learning. San Francisco: Morgan Kaufmann, 2000, pp. 359-366
13. Duan KB, Rajapakse JC, Wang H et al. Multiple SVM-RFE for gene selection in cancer classification with expression data. IEEE Trans Nanobiosci 2005; 4: 228-234
14. Ding C, Peng H. Minimum redundancy feature selection from microarray gene expression data. J Bioinform Comput Biol 2005; 3: 185-205
15. Breiman L. Random forests. Mach Learn 2001; 45: 5-32
16. Duda OR, Heart PE, Stork DG. Pattern Classification. New York: John Wiley & Sons, 2001
17. Vapnik VN. Statistical Learning Theory. New York: John Wiley & Sons, 1988
18. Bobrowski L. Data Mining Based on Complex and Piecewise Linear (CPL) Criterion Functions. [in Polish]. Bialystok, Poland: Bialystok University of Technology, 2005
19. Ooi SQ, Chan RM, Poh LK et al. Visfatin and its genetic variants are associated with obesity-related morbidities and cardiometabolic risk in severely obese children. Pediatr Obes 2014; 9: 81-91
20. Wang LS, Yan JJ, Tang NP et al. A polymorphism in the visfatin gene promoter is related to decreased plasma levels of inflammatory markers in patients with coronary artery disease. Mol Biol Rep 2011; 38: 819-825
21. Friese MA, Jones EY, Fugger L. MHC II molecules in inflammatory diseases: interplay of qualities and quantities. Trends Immunol 2005; 26: 559-561
22. Gyllenberg A, Piehl F, Alfredsson L et al. Variability in the CIITA gene interacts with HLA in multiple sclerosis. Genes Immun 2014; 15: 162-167
23. Bronson PG, Goldstein BA, Ramsay PP et al. The rs4774 CIITA missense variant is associated with risk of systemic lupus erythematosus. Genes Immun 2011; 12: 667-671
24. Fibrinogen Studies Collaboration, Kaptoge S, White IR et al. Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: individual participant meta-analysis of 154,211 adults in 31 prospective studies: the fibrinogen studies collaboration. Am J Epidemiol 2007; 166: 867-879
25. Chambers JC, Zhang W, Lord GM et al. Genetic loci influencing kidney function and chronic kidney disease. Nat Genet 2010; 42: 373-375
26. Buendia P, Montes de Oca A, Madueno JA et al. Endothelial microparticles mediate inflammation-induced vascular calcification. FASEB J 2015; 29: 173-181
27. Suh JS, Hahn WH, Lee JS et al. Coding polymorphisms of bone morphogenetic protein 2 contribute to the development of childhood IgA nephropathy. Exp Ther Med 2011; 2: 337-341
28. Okaniwa N, Sasaki M, Mizushima T et al. eNOS plays an important role in the regulation of colonic inflammation: a novel therapeutic target and a predictive marker for the prognosis of ulcerative colitis. Free Radical Res 2015; 49: 35-44
29. Liu Y, Burdon KP, Langefeld CD et al. T-786C polymorphism of the endothelial nitric oxide synthase gene is associated with albuminuria in the diabetes heart study. J Am Soc Nephrol 2005; 16: 1085-1090
30. Ned RM, Yesupriya A, Imperatore G et al. Inflammation gene variants and susceptibility to albuminuria in the U.S. population: analysis in the Third National Health and Nutrition Examination Survey (NHANES III), 1991-1994. BMC Med Genet 2010; 11: 155
31. Han Y, Xu W, Zhang W et al. T-786C polymorphism in the endothelial nitric oxide synthase gene is associated with increased risk of coronary artery disease in a Chinese population. Pharmacology 2010; 85: 211-216
32. Dellamea BS, Pinto LC, Leitao CB et al. Endothelial nitric oxide synthase gene polymorphisms and risk of diabetic nephropathy: a systematic review and meta-analysis. BMC Med Genet 2014; 15: 9
33. Ezzidi I, Mtiraoui N, Mohamed MB et al. Association of endothelial nitric oxide synthase Glu298Asp, 4b/a, and -786T > C gene variants with diabetic nephropathy. J Diabetes Complicat 2008; 22: 331-338
34. Yamada Y, Kato K, Oguri M et al. Association of genetic variants with atherothrombotic cerebral infarction in Japanese individuals with metabolic syndrome. Int J Mol Med 2008; 21: 801-808
35. Miyamoto Y, Saito Y, Nakayama M et al. Replication protein A1 reduces transcription of the endothelial nitric oxide synthase gene containing a -786T→C mutation associated with coronary spastic angina. Hum Mol Genet 2000; 9: 2629-2637
36. Haynes DR. Emerging and future therapies for the treatment of bone loss associated with chronic inflammation. Inflammopharmacology 2006; 14: 193-197
37. Leibbrandt A, Penninger JM. RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci 2008; 1143: 123-150
38. Moseley KF. Type 2 diabetes and bone fractures. Curr Opin Endocrinol Diabetes Obes 2012; 19: 128-135
39. Clement K, Le Stunff C, Meirhaeghe A et al. In obese and non-obese adults, the cis-regulatory rs361072 promoter variant of PIK3CB is associated with insulin resistance not with type 2 diabetes. Mol Genet Metab 2009; 96: 129-132
40. Le Stunff C, Dechartres A, Mariot V et al. Association analysis indicates that a variant GATA-binding site in the PIK3CB promoter is a Cis-acting expression quantitative trait locus for this gene and attenuates insulin resistance in obese children. Diabetes 2008; 57: 494-502
41. Le Stunff C, Dechartres A, Miraglia Del Giudice E et al. A single-nucleotide polymorphism in the p110beta gene promoter is associated with partial protection from insulin resistance in severely obese adolescents. J Clin Endocrinol Metab 2008; 93: 212-215
42. Jia SH, Li Y, Parodo J et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004; 113: 1318-1327
43. Catalan V, Gomez-Ambrosi J, Rodriguez A et al. Association of increased visfatin/PBEF/NAMPT circulating concentrations and gene expression levels in peripheral blood cells with lipid metabolism and fatty liver in human morbid obesity. Nutr Metab Cardiovasc Dis 2011; 21: 245-253
44. Friebe D, Neef M, Kratzsch J et al. Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans. Diabetologia 2011; 54: 1200-1211
45. Ting JP, Trowsdale J. Genetic control of MHC class II expression. Cell 2002; 109 (Suppl): S21-S33
46. LeibundGut-Landmann S, Waldburger JM, Krawczyk M et al. Mini-review: Specificity and expression of CIITA, the master regulator of MHC class II genes. Eur J Immunol 2004; 34: 1513-1525
47. Tanos BE, Yang HJ, Soni R et al. Centriole distal appendages promote membrane docking, leading to cilia initiation. Genes Dev 2013; 27: 163-168
48. van Bon BW, Oortveld MA, Nijtmans LG et al. CEP89 is required for mitochondrial metabolism and neuronal function in man and fly. Hum Mol Genet 2013; 22: 3138-3151
49. Wozney JM, Rosen V. Bone morphogenetic protein and bone morphogenetic protein gene family in bone formation and repair. Clin Orthop Relat Res 1998; 346: 26-37
50. Miller PD. Chronic kidney disease and osteoporosis: evaluation and management. Bone Key Rep 2014; 3: 542
51. Lorenzo J, Horowitz M, Choi Y. Osteoimmunology: interactions of the bone and immune system. Endocr Rev 2008; 29: 403-440
52. Dosenko VE, Zagoriy VY, Haytovich NV et al. Allelic polymorphism of endothelial NO-synthase gene and its functional manifestations. Acta Bio-chim Pol 2006; 53: 299-302
53. Sage AP, Tintut Y, Demer LL. Regulatory mechanisms in vascular calcification. Nat Rev Cardiol 2010; 7: 528-536
54. Suliman ME, Garcia-Lopez E, Anderstam B et al. Vascular calcification inhibitors in relation to cardiovascular disease with special emphasis on fetuin-A in chronic kidney disease. Adv Clin Chem 2008; 46: 217-262
55. Khan AH, Pessin JE. Insulin regulation of glucose uptake: a complex interplay of intracellular signalling pathways. Diabetologia 2002; 45: 1475-1483
56. Jung M, Sabat R, Kratzschmar J et al. Expression profiling of IL-10regulated genes in human monocytes and peripheral blood mononuclear cells from psoriatic patients during IL-10 therapy. Eur J Immunol 2004; 34: 481-493
57. Cartier A, Cote M, Lemieux I et al. Sex differences in inflammatory markers: what is the contribution of visceral adiposity? Am J Clin Nutr 2009; 89: 1307-1314
58. Park HS, Park JY, Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. Diabetes Res Clin Pract 2005; 69: 29-35
59. Bataille R, Klein B. C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. Arthritis Rheum 1992; 35: 982-984
60. Davalos D, Akassoglou K. Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol 2012; 34: 43-62
61. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990; 265: 621-636
62. Carlson CS, Aldred SF, Lee PK et al. Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet 2005; 77: 64-77
63. Hsu LA, Chang CJ, Wu S et al. Association between functional variants of the ICAM1 and CRP genes and metabolic syndrome in Taiwanese subjects. Metabolism 2010; 59: 1710-1716
64. Kathiresan S, Larson MG, Vasan RS et al. Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level. Circulation 2006; 113: 1415-1423
65. Snaedal S, Heimburger O, Qureshi AR et al. Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival. Am J Kidney Dis 2009; 53: 1024-1033